Wirkstoffe & Arzneimittelsicherheit

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (83)

Wechselwirkungen · Akynzeo

Akynzeo 300 mg/0.5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5

HOS-130696 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) duloxetine (HOS-089666) venlafaxine (HOS-086573) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) fluvoxamine (HOS-085908) escitalopram (HOS-129417)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 7496998149251e36b5a5979e551a8455c10917990713c719e5f50b629ca93bb4 · Zeichen 3396–3695 im Abschnitt

Wechselwirkungen · Akynzeo

Akynzeo 235 mg/0.25 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 21

HOS-130738 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Akynzeo

Akynzeo 235 mg/0.25 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 39

HOS-130781 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Akynzeo

Akynzeo 300 mg/0.5 mg oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 56

HOS-130817 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Gegenanzeigen · Fintepla

Fintepla 2.2 mg/ml oral solution · Abschnitt 4.3 · PDF-Seite 5

HOS-132963 · Präparat HOS-097342

Hypersensitivity to the active substance or any of the excipients listed in section 6.1. Aortic or mitral valvular heart disease. Pulmonary arterial hypertension. Within 14 days of the administration of monoamine oxidase inhibitors due to an increased risk of serotonin syndrome.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-09T15:00:00Z · SHA-256 e175f94af1e49d4a11fbbc3e861df1256bc1a0a5d612baaf0706babc5f1fc781 · Passage dc0637ea56029702bee17ce5bffb21c252c423da1c96d42e2482c5dc98c00eea · Zeichen 0–279 im Abschnitt

Wechselwirkungen · Fintepla

Fintepla 2.2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 8

HOS-132965 · Präparat HOS-097342

Pharmacodynamic interactions with other central nervous system depressants increase the risk of aggravated central nervous system depression. Examples of such depressants are other serotonergic medicinal products (including SSRIs, SNRIs, tricyclic antidepressants, or triptans); medicinal products that impair metabolism of serotonin such as MAOIs; or antipsychotics that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-09T15:00:00Z · SHA-256 e175f94af1e49d4a11fbbc3e861df1256bc1a0a5d612baaf0706babc5f1fc781 · Passage 67fa5839cca9c945c4f86c15e8a157855888ce45e16b832d0bd4bf24acea3cf3 · Zeichen 30–482 im Abschnitt

Wechselwirkungen · Duloxetine Zentiva

Duloxetine Zentiva 30 mg gastro-resistant hard capsules Duloxetine Zentiva 60 mg gastro-resistant hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-133004 · Präparat HOS-097350

Due to the risk of serotonin syndrome, duloxetine should not be used in combination with non-selective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of duloxetine, at least 5 days should be allowed after stopping Duloxetine Zentiva before starting an MAOI (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-11-29T16:00:00Z · SHA-256 a6188d2978ea09f7e5b7445a447f5e2a57efdecb0d31b2c6eef34f98353221c3 · Passage c3448583f62b3b277b4d0551fe7035e3a7c2165b807c9a7501a87fea81ba591e · Zeichen 38–408 im Abschnitt

Wechselwirkungen · Duloxetine Zentiva

Duloxetine Zentiva 30 mg gastro-resistant hard capsules Duloxetine Zentiva 60 mg gastro-resistant hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-133011 · Präparat HOS-097350

In rare cases, serotonin syndrome has been reported in patients using SSRIs/SNRIs concomitantly with serotonergic agents. Caution is advisable if duloxetine is used concomitantly with serotonergic agents like SSRIs, SNRIs, tricyclic antidepressants like clomipramine or amitriptyline, MAOIs like moclobemide or linezolid, St. John’s wort (Hypericum perforatum) or triptans, buprenorphine, tramadol, pethidine and tryptophan (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amitriptyline (HOS-085911) tryptophan (HOS-112872) moclobemide (HOS-087879) buprenorphine (HOS-086193) serotonin (HOS-085477) clomipramine (HOS-085906) linezolid (HOS-112865) tramadol (HOS-112871)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-11-29T16:00:00Z · SHA-256 a6188d2978ea09f7e5b7445a447f5e2a57efdecb0d31b2c6eef34f98353221c3 · Passage 8a402fa89c73f43016b0e55a2445bff7db6e289a2e3d7609d0b5bb0f81d2d18f · Zeichen 1680–2122 im Abschnitt

Wechselwirkungen · Duloxetine Lilly

Duloxetine Lilly 30 mg hard gastro-resistant capsules Duloxetine Lilly 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 7

HOS-133570 · Präparat HOS-097464

Monoamine oxidase inhibitors (MAOIs): Due to the risk of serotonin syndrome, duloxetine should not be used in combination with non-selective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of duloxetine, at least 5 days should be allowed after stopping Duloxetine Lilly before starting an MAOI (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-09T15:33:00Z · SHA-256 61054d41822a6a0df108fca29fbebcc411cb952e97947b2c207af5bcdba0577a · Passage c616dd299c55a0050a816f12989bec40ab8cf084398c9d79bccb06d39fac1816 · Zeichen 0–406 im Abschnitt

Wechselwirkungen · Duloxetine Lilly

Duloxetine Lilly 30 mg hard gastro-resistant capsules Duloxetine Lilly 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 7

HOS-133578 · Präparat HOS-097464

Serotonergic agents: In rare cases, serotonin syndrome has been reported in patients using SSRIs/SNRIs concomitantly with serotonergic agents. Caution is advisable if Duloxetine Lilly is used concomitantly with serotonergic agents like SSRIs, SNRIs, tricyclic antidepressants like clomipramine or amitriptyline, MAOIs like moclobemide or linezolid, St John’s wort (Hypericum perforatum) or triptans, tramadol, pethidine and tryptophan (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amitriptyline (HOS-085911) tryptophan (HOS-112872) moclobemide (HOS-087879) serotonin (HOS-085477) clomipramine (HOS-085906) linezolid (HOS-112865) tramadol (HOS-112871)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-09T15:33:00Z · SHA-256 61054d41822a6a0df108fca29fbebcc411cb952e97947b2c207af5bcdba0577a · Passage e7cb597765284af6ec3c062bad310b4fb7ba8c201087b248f61c8cdef20e354e · Zeichen 1665–2118 im Abschnitt

Wechselwirkungen · Aripiprazole Sandoz

Aripiprazole Sandoz 5 mg tablets Aripiprazole Sandoz 10 mg tablets Aripiprazole Sandoz 15 mg tablets Aripiprazole Sandoz 20 mg tablets Aripiprazole Sandoz 30 mg tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-133673 · Präparat HOS-097480

Serotonin syndrome Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-08-21T11:00:00Z · SHA-256 327ef54b8c9603e9d2d852929d852cc6b552a07adfbdb4be62ec8d86171c0375 · Passage ad67507334f8f89df694cf33f81f0fa11e9f6235e2a327e39d72e545da77ba0b · Zeichen 5050–5506 im Abschnitt

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19–20

HOS-134030 · Präparat HOS-097520

19 Medicinal product by Effects on medicinal product Recommendation concerning therapeutic areas levels. co-administration with Genvoya Mean percent change in AUC, Cmax, Cmin1 Tricyclic antidepressants (TCAs) Interaction not studied with any of Careful dose titration of the Trazodone the components of Genvoya. antidepressant and monitoring for Selective serotonin reuptake antidepressant response is inhibitors (SSRIs) Concentrations of antidepressant recommended. Escitalopram agents may be increased when co-administered with cobicistat. IMMUNOSUPPRESSANTS Ciclosporin Interaction not studied with any of Therapeutic monitoring is Sirolimus the components of Genvoya. recommended upon Tacrolimus co-administration with Genvoya. Concentrations of these immunosuppressant agents may be increased when administered with cobicistat. SEDATIVES/HYPNOTICS Buspirone Interaction not studied with any of Co-administration of Genvoya and Clorazepate the components of Genvoya. triazolam is contraindicated (see Diazepam section 4.3). With other Estazolam Triazolam is primarily metabolised sedatives/hypnotics, dose reduction Flurazepam by CYP3A. Co-administration may be necessary and concentration Lorazepam with Genvoya may result in monitoring is recommended. Triazolam increased plasma concentrations of Zolpidem this medicinal product, which is associated with the potential for serious or life-threatening adverse reactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) lorazepam (HOS-085981) diazepam (HOS-085904) zolpidem (HOS-086327) serotonin (HOS-085477) trazodone (HOS-086251) tacrolimus (HOS-085202) buspirone (HOS-086325) sirolimus (HOS-085172) escitalopram (HOS-129417) triazolam (HOS-086168) flurazepam (HOS-086166)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 5942209e475c796ef61c4b0bb67f6fad6953705ca4043b5a69de6960506043d8 · Zeichen 46301–48689 im Abschnitt

Wechselwirkungen · Palonosetron Accord

Palonosetron Accord 250 micrograms solution for injection · Abschnitt 4.5 · PDF-Seite 4

HOS-135569 · Präparat HOS-097730

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic drugs (including SSRIs and SNRIs).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-02-20T11:10:00Z · SHA-256 2404468d027dfe60f8107c0349ddcf4fe941a3afb092543c2026d50144230a9d · Passage 44c8c773b643ddc7420dd935fffd813e8eb2c605c291145ecd3cb296deb6acdb · Zeichen 1222–1372 im Abschnitt

Wechselwirkungen · Dzuveo

Dzuveo 30 micrograms sublingual tablet · Abschnitt 4.5 · PDF-Seite 5

HOS-137933 · Präparat HOS-098113

Co-administration of sufentanil with a serotonergic agent, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), or Monoamine Oxidase Inhibitors (MAOIs), may increase the risk of serotonin syndrome, a potentially life threatening condition. Monoamine Oxidase Inhibitors must not be taken in the 2 weeks before or at the same time as Dzuveo is given.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-08-04T09:41:00Z · SHA-256 11a627f517ef165f1c214a9467017376a3e2707d6037112cbc10731d39d973c1 · Passage 362400cc2eed0f3596c494ae51f36bfc8ef6c06f759c062950aff04f44c8b2b7 · Zeichen 1882–2288 im Abschnitt

Wechselwirkungen · Zubsolv

Zubsolv 0.7 mg/0.18 mg sublingual tablets Zubsolv 1.4 mg/0.36 mg sublingual tablets Zubsolv 2.9 mg/0.71 mg sublingual tablets Zubsolv 5.7 mg/1.4 mg sublingual tablets Zubsolv 8.6 mg/2.1 mg sublingual tablets Zubsolv 11.4 mg/2.9 mg sublingual tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-138581 · Präparat HOS-098216

Zubsolv should be used cautiously when co-administered with: • Sedatives such as benzodiazepines or related medicinal products The concomitant use of opioids with sedative medicinal products such as benzodiazepines or related medicinal products increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use of sedative medicinal products should be limited (see section 4.4). Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines while taking this medicinal product and should also be cautioned to use benzodiazepines concurrently with this medicinal product only as directed by their physician (see section 4.4). • The concomitant use of Zubsolv with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death (see section 4.4). • Other central nervous system depressants, other opioid derivatives (e.g. methadone, analgesics and antitussives), certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, neuroleptics, clonidine and related substances: these combinations increase central nervous system depression. The reduced level of alertness can make driving and using machines hazardous. • Furthermore, adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving buprenorphine/naloxone. Therefore the potential to overdose with a full agonist exists, especially when attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are declining • Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4) • naltrexone and nalmefene are opioid antagonists that can block the pharmacological effects of buprenorphine. Co-administration during buprenorphine/naloxone treatment is 9 contraindicated due to the potentially dangerous interaction that may precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms (see section 4.3). • CYP3A4 inhibitors: an interaction study of buprenorphine with ketoconazole (a potent inhibitor of CYP3A4) resulted in increased Cmax and AUC (area under the curve) of buprenorphine (approximately 50 % and 70 % respectively) and, to a lesser extent, of norbuprenorphine Patients receiving Zubsolv should be closely monitored, and may require dose-reduction if combined with potent CYP3A4 inhibitors (e.g. protease inhibitors like ritonavir, nelfinavir or indinavir or azole antifungals such as ketoconazole or itraconazole, macrolide antibiotics). • CYP3A4 inducers: Concomitant use of CYP3A4 inducers with buprenorphine may decrease buprenorphine plasma concentrations, potentially resulting in sub-optimal treatment of opioid dependence with buprenorphine. It is recommended that patients receiving buprenorphine/naloxone should be closely monitored if inducers (e.g. phenobarbital, carbamazepine, phenytoin, rifampicin) are co-administered. The dose of buprenorphine or the CYP3A4 inducer may need to be adjusted accordingly. • The concomitant use of monoamine oxidase inhibitors (MAOI) might produce exaggeration of the effects of opioids, based on experience with morphine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) pregabalin (HOS-112893) norepinephrine (HOS-090547) nelfinavir (HOS-084520) methadone (HOS-086198) protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) clonidine (HOS-088594) carbamazepine (HOS-085618) naltrexone (HOS-115836) nalmefene (HOS-115837) morphine (HOS-086053) gabapentin (HOS-090745) serotonin (HOS-085477) itraconazole (HOS-084516) ritonavir (HOS-084521) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-08T09:49:00Z · SHA-256 5abf2fbb0a7fd36ed1be04f576c9d6b4a021a25a707c692fa21b326376a4f2b5 · Passage 36507a34d513c06aeda586e977de80135455da379f00364e466d3a649d3e2c11 · Zeichen 232–4044 im Abschnitt

Wechselwirkungen · Buvidal

Buvidal 8 mg prolonged-release solution for injection Buvidal 16 mg prolonged-release solution for injection Buvidal 24 mg prolonged-release solution for injection Buvidal 32 mg prolonged-release solution for injection · Abschnitt 4.5 · PDF-Seite 8

HOS-140298 · Präparat HOS-098498

Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioid antagonists that can block the pharmacological effects of buprenorphine. For opioid-dependent patients currently receiving buprenorphine treatment, naltrexone may precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms. For patients currently receiving naltrexone treatment, the intended therapeutic effects of buprenorphine administration may be blocked by naltrexone. • alcoholic drinks or medicinal products containing alcohol as alcohol increases the sedative effect of buprenorphine (see section 4.7). • benzodiazepines: This combination may result in death due to respiratory depression of central origin. Therefore, dosages must be closely monitored and this combination must be avoided in cases where there is a risk of misuse. Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines whilst taking this product, and should also be cautioned to use benzodiazepines concurrently with this product only as directed by their physician (see section 4.4). • gabapentinoids: The concomitant use of Buvidal with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death. Therefore, dosages must be closely monitored and this combination must be avoided in cases where there is a risk of misuse. Patients should be cautioned to use gabapentinoids concurrently with this product only as directed by their physician (see section 4.4). • Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4). • other central nervous system depressants: Other opioid derivatives (e.g. methadone, analgesics and antitussives); certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, antipsychotics, clonidine and related substances. These combinations increase central nervous system depression. The reduced level of alertness can make driving and using machinery hazardous (see section 4.7). • opioid analgesics: Adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving buprenorphine. The potential for overdose also exists with a full agonist, especially when attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are declining (see section 4.4) • Buprenorphine is metabolised to norbuprenorphine primarily by CYP3A4. Interaction with co- administered inducers or inhibitors have been established in studies using transmucosal and transdermal buprenorphine. Buprenorphine is also metabolised to buprenorphine-3β- glucuronide by UGT1A1. • CYP3A4 inhibitors may inhibit the metabolism of buprenorphine resulting in increased Cmax and AUC of buprenorphine and norbuprenorphine. Buvidal avoids first-pass effects and CYP3A4 inhibitors (e.g. protease inhibitors like ritonavir, nelfinavir or indinavir, or azole antifungals such as ketoconazole or itraconazole, or macrolide antibiotics) are

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) pregabalin (HOS-112893) norepinephrine (HOS-090547) nelfinavir (HOS-084520) methadone (HOS-086198) protease (HOS-085623) ketoconazole (HOS-084513) clonidine (HOS-088594) naltrexone (HOS-115836) nalmefene (HOS-115837) gabapentin (HOS-090745) serotonin (HOS-085477) itraconazole (HOS-084516) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-21T17:42:00Z · SHA-256 1ad9ce13109b545d01c45ffd56cec5dc90c2b7294f4e2ae1f7e5e985c1a064eb · Passage 2507cd2f2663aa4a74d791faab2504c7371d895671fa1111e3aab02507c0c573 · Zeichen 58–3582 im Abschnitt

Wechselwirkungen · Buvidal

Buvidal 64 mg prolonged-release solution for injection Buvidal 96 mg prolonged-release solution for injection Buvidal 128 mg prolonged-release solution for injection Buvidal 160 mg prolonged-release solution for injection · Abschnitt 4.5 · PDF-Seite 24

HOS-140339 · Präparat HOS-098498

Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioid antagonists that can block the pharmacological effects of buprenorphine. For opioid-dependent patients currently receiving buprenorphine treatment, naltrexone may precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms. For patients currently receiving naltrexone treatment, the intended therapeutic effects of buprenorphine administration may be blocked by naltrexone. • alcoholic drinks or medicinal products containing alcohol as alcohol increases the sedative effect of buprenorphine (see section 4.7). • benzodiazepines: This combination may result in death due to respiratory depression of central origin. Therefore, dosages must be closely monitored and this combination must be avoided in cases where there is a risk of misuse. Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines whilst taking this product, and should also be cautioned to use benzodiazepines concurrently with this product only as directed by their physician (see section 4.4). • gabapentinoids: The concomitant use of Buvidal with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death. Therefore, dosages must be closely monitored and this combination must be avoided in cases where there is a risk of misuse. Patients should be cautioned to use gabapentinoids concurrently with this product only as directed by their physician (see section 4.4). • Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4). • other central nervous system depressants: Other opioid derivatives (e.g. methadone, analgesics and antitussives); certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, antipsychotics, clonidine and related substances. These combinations increase central nervous system depression. The reduced level of alertness can make driving and using machinery hazardous (see section 4.7). • opioid analgesics: Adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving buprenorphine. The potential for overdose also exists with a full agonist, especially when attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are declining (see section 4.4) • Buprenorphine is metabolised to norbuprenorphine primarily by CYP3A4. Interaction with co- administered inducers or inhibitors have been established in studies using transmucosal and transdermal buprenorphine. Buprenorphine is also metabolised to buprenorphine-3β- glucuronide by UGT1A1. • CYP3A4 inhibitors may inhibit the metabolism of buprenorphine resulting in increased Cmax and AUC of buprenorphine and norbuprenorphine. Buvidal avoids first-pass effects and CYP3A4 inhibitors (e.g. protease inhibitors like ritonavir, nelfinavir or indinavir, or azole antifungals such as ketoconazole or itraconazole, or macrolide antibiotics) are expected to have less effects on buprenorphine metabolism when co-administered with Buvidal as compared to when co-administered with sublingual buprenorphine. When switching from sublingual buprenorphine to Buvidal, patients may need to be monitored to ensure plasma buprenorphine levels are adequate. Patients already on Buvidal who start treatment with CYP3A4 inhibitors should be treated with weekly Buvidal and be monitored for signs and symptoms of overtreatment. Conversely, if a patient who is concomitantly treated with Buvidal and a CYP3A4

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) pregabalin (HOS-112893) norepinephrine (HOS-090547) nelfinavir (HOS-084520) methadone (HOS-086198) protease (HOS-085623) ketoconazole (HOS-084513) clonidine (HOS-088594) naltrexone (HOS-115836) nalmefene (HOS-115837) gabapentin (HOS-090745) serotonin (HOS-085477) itraconazole (HOS-084516) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-21T17:42:00Z · SHA-256 1ad9ce13109b545d01c45ffd56cec5dc90c2b7294f4e2ae1f7e5e985c1a064eb · Passage a29834a297e58897f230ac85a5938fedfb1c445658da5ff294f0999631e2634e · Zeichen 58–4215 im Abschnitt

Wechselwirkungen · Xospata

Xospata 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-141419 · Präparat HOS-098642

5HT2B receptor or sigma nonspecific receptor Based on in vitro data, gilteritinib may reduce the effects of medicinal products that target 5HT2B receptor or sigma nonspecific receptor (selective serotonin reuptake inhibitors e.g., escitalopram, fluoxetine, sertraline). Avoid concomitant use of these medicinal products with gilteritinib unless use is considered essential for the care of the patient.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) escitalopram (HOS-129417)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-09T15:12:00Z · SHA-256 c553334e12e70f11f6e5ebf231d99102b822bac3002cf0bd26bc31c72e26836b · Passage 1303eefa2bbbc61d5477819574b1477da8b7f91437c34ee074bcd45a6788b099 · Zeichen 2602–3003 im Abschnitt

Wechselwirkungen · Celsunax

Celsunax 74 MBq/mL solution for injection · Abschnitt 4.5 · PDF-Seite 4

HOS-144558 · Präparat HOS-099208

Ioflupane binds to the dopamine transporter. Active substances that bind to the dopamine transporter with high affinity may therefore interfere with Celsunax diagnosis. These include: - amfetamine, - bupropion, - cocaine, - codeine, - dexamfetamine, - methylphenidate, - modafinil, - phentermine, - Selective serotonin reuptake inhibitors, such as sertraline, may increase or decrease ioflupane binding to the dopamine transporter.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) codeine (HOS-090544) modafinil (HOS-090546) dopamine (HOS-085948) methylphenidate (HOS-090545) cocaine (HOS-090543) phentermine (HOS-087483) serotonin (HOS-085477) sertraline (HOS-086247)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-11-27T15:11:25Z · SHA-256 77f392cb104456c9cbc8546562c76801289c05a366ec191df15a8724cf4a4bf6 · Passage 0e2070ab529a35255aec2dd066079e44b60a55d57a34e1fe3acee90b466443da · Zeichen 55–540 im Abschnitt

Wechselwirkungen · Rayvow

RAYVOW 50 mg film-coated tablets RAYVOW 100 mg film-coated tablets RAYVOW 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4

HOS-146380 · Präparat HOS-099510

Concomitant administration of lasmiditan and medicinal products (e.g., SSRIs, SNRIs, TCAs) that increase serotonin may increase the risk of serotonin syndrome. Clinical experience for the use of

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lasmiditan (HOS-146374) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-02-06T14:15:00Z · SHA-256 1e249810461a190ad08f26cfa9c8836cc5710c80820c828a4ea6df354808f0a7 · Passage e2c092f3484115171a315e968baf1ce299761957a96f468f192030a8cb46558c · Zeichen 492–686 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.